pharmaphorum

MARCH 11, 2022

Qulipta was approved by the FDA last September for the preventive treatment of episodic migraine, a few months later than its main rival in the oral CGRP category, Biohaven’s Nurtec ODT (rimegepant), got a green light for the same indication. billion by 2027.

Labelling 52

Labelling FDA 52

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. weight reduction in obese individuals, as per its label. Results from this trial are scheduled to be released in October 2027, and may allow non-diabetic obese patients to have access to Mounjaro.

Labelling 105

Labelling Insurance Communication FDA 105

pharmaphorum

JANUARY 10, 2023

New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical “game changers,” according to Clarivate.

FDA 52

FDA Labelling 52

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. weight reduction in obese individuals, as per its label. Results from this trial are scheduled to be released in October 2027, and may allow non-diabetic obese patients to have access to Mounjaro.

Labelling 98

Labelling Insurance Communication FDA 98

European Pharmaceutical Review

FEBRUARY 22, 2023

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. Results from the first open-label, single-centre study of RT-101,6 which was conducted in Australia, were reported at the start of 2020.

Immunization 105

Immunization Packaging Labelling FDA 105

Pharmaceutical Technology

JANUARY 10, 2023

Specifically, across all the major classes there are significant developments, label updates, and biosimilar launches that are driving their growth.

Labelling 52

Labelling Pharmaceutical Companies Pharmaceutical Companies Compounding 52

The Checkup by Singlecare

OCTOBER 9, 2024

While Lumigan is a 0.01% solution of bimatoprost and no generic product is manufactured at this concentration, patents on Lumigan expire in 2025 and 2027, so there may be a generic option approved by the Food and Drug Administration (FDA) thereafter. Generic bimatoprost drops are available at a 0.03% concentration currently.

Insurance 52

Insurance Insurance Coverage Labelling FDA 52

Pharmaceutical Technology

APRIL 24, 2023

Covid-19 vaccines from Moderna and Pfizer /BioNTech, which use lipid nanoparticles, became the only two FDA-approved vaccines for almost all ages. However, after a period of slow movement in the field, the FDA approved the first nanodrug, Doxil, for Kaposi sarcoma in 1995. GlobalData is the parent company of Pharmaceutical Technology.

Vaccines 59

Vaccines Immunization Medical Schools FDA 59

The FDA Law Blog

JULY 10, 2025

Snow & Riëtte van Laack — Two southern states are taking bold steps to change the way they approach food labeling—and they’re not mincing words. Texas Goes BIG on Food Warnings Beginning on January 1, 2027, Texans may notice new warning labels on some food products sold in their fair state. By Charles D. Synthetic dyes.

Labelling 66

Labelling Packaging FDA Communication 66

The Checkup by Singlecare

APRIL 22, 2025

The FDA first approved vortioxetine to treat major depressive disorder in 2013. That might differ slightly in the US, but even when the Trintellix patent ends in 2026, its generic probably wont debut until 2027 or later. What are the off-label uses for Trintellix? So some doctors prescribe it off-label for anxiety as well.

Insurance 52

Insurance Insurance Coverage Prescription Filling Health Insurance Companies 52